GlassScriptPhysician profile
Anupama Mohanram
NPI 1083679724
$11,380.29
in general payments reported to CMS, 2019-2025
27 companies · $1,343 in 2025
The $1,343 reported for 2025 was more than what 84% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $341 · 2020: $1,432 · 2021: $4,532 · 2022: $699 · 2023: $1,401 · 2024: $1,632 · 2025: $1,343.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,272 · Education: $104.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,271.96 |
| Education | $104.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, INC. | $4,505.42 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $2,162.30 | 2020-2025 | Farxiga, Lokelma |
| Novo Nordisk INC | $1,200.65 | 2021-2025 | Ozempic, Wegovy |
| Otsuka America Pharmaceutical, INC. | $673.79 | 2019-2024 | Jynarque |
| Mallinckrodt Hospital Products INC. | $493.55 | 2020-2025 | Terlivaz |
| Bayer Healthcare Pharmaceuticals INC. | $402.26 | 2021-2024 | |
| E.R. Squibb & Sons, L.L.C. | $239.10 | 2019-2020 | |
| Amgen INC. | $205.17 | 2023-2024 | Krystexxa |
| Madrigal Pharmaceuticals | $182.21 | 2024-2025 | Rezdiffra, Resmetirom |
| Esperion Therapeutics, INC. | $154.89 | 2022-2025 | Nexletol |
| Travere Therapeutics, INC. | $131.66 | 2022-2023 | |
| Lexicon Pharmaceuticals, INC. | $125.50 | 2024 | Inpefa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $124.60 | 2025 | Jardiance |
| Glaxosmithkline, LLC. | $121.83 | 2024 | Benlysta |
| Aurinia Pharma U.S., INC. | $116.36 | 2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $107.84 | 2023 | Krystexxa |
| Vifor Pharma, INC. | $99.92 | 2020-2024 | Veltassa, Korsuva |
| Novartis Pharmaceuticals Corporation | $95.81 | 2024-2025 | |
| Janssen Scientific Affairs, LLC | $56.14 | 2022-2023 | Xarelto |
| Boston Scientific Corporation | $44.19 | 2023 | |
| Opko Pharmaceuticals, LLC | $29.04 | 2020 | |
| Calliditas Therapeutics US INC. | $23.56 | 2023 | Tarpeyo |
| Ardelyx, INC. | $21.23 | 2025 | Ibsrela |
| Nxstage Medical, INC. | $20.32 | 2024 | |
| Abbvie INC. | $15.52 | 2023 | |
| Arbor Pharmaceuticals, INC. | $14.98 | 2020 | |
| Amarin Pharma, INC. | $12.45 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anupama Mohanram listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.